A Behavioral Intervention to Prevent Gestational Diabetes Mellitus
NCT ID: NCT03987412
Last Updated: 2019-09-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
1200 participants
INTERVENTIONAL
2019-08-16
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators hypothesis that behavioral intervention from the first trimester of pregnancy with mobile APP that incorporates nutrition, exercise and phycological support will:
1. Reduce the risk of developing GDM in pregnant women with risks of GDM.
2. Improve the pregnant women's adherence of behavioral intervention and their satisfaction of prenatal medical care.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Early Nutrition Intervention on the Incidence of High-risk Patients With Gestational Diabetes
NCT03550976
Medical Nutrition Therapy Intervention Program for Women With Gestational Diabetes--a Prospective Study
NCT02893072
Prevention of Gestational Diabetes Mellitus With Lifestyle Intervention Among Women of Advanced Maternal Age.
NCT05421845
Gestational Lifestyle & Outcomes Wellness
NCT07263412
Prevention of Gestational Diabetes
NCT01130012
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Women who meet the eligibility criteria and who are willing to provide informed consent will be enrolled and randomized to behavioral intervention group and control group. Women in the behavioral intervention group will be educated about the risks of GDM, and then applied with a mobile APP that provides nutrition, exercise and phycological support starting from their first trimester. This behavioral support will be modified individually and continuously according to the pregnant women's feedback of their daily performance through the APP. Both groups will have regular prenatal care.
During 24-28 gestational weeks, GDM will be diagnosed by a 75g oral glucose tolerance test (OGTT) according to the new World Health Organization criteria as fasting glucose level in fasting whole blood ≥5.1mmol/L, or 1-hour value ≥10.0mmol/l, or 2-hour value ≥8.5mmol/L. Investigators will compare the GDM risk in the two groups to evaluate whether behavioral intervention with mobile APP can reduce the risk of GDM in Chinese pregnant women who are at high risk of GDM. Participants' adherence with the behavioral intervention will be evaluated by analyzing the data collected by the APP, and participants' satisfaction of the prenatal care will be evaluated with questionnaires during 24-28 gestational weeks. Intervention with the APP will be stopped in the third trimester. All the participates will receive standard medical management until they give birth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Behavioral intervention
Pregnant women randomized to the behavioral intervention group will recieve a face-to-face education about the risks of GDM at their local rearch centers. Then they will be provided with a mobile APP incorporating nutrition, exercise and phycological support. They will also have regular prenatal care in their local hospitals.
Lifestyle intervention with APP
The face to face education class will be conducted by an obstetrician, an endocrinologist and a nutritionist together. Then the lifestyle intervention will be launched by an APP that installed in participants' private mobile phones, including nutrition, exercise and phycological support. Nutrition guidance is conducted according to the Chinese Dietary Guide, Chinese and international guidelines of gestation diabetes management. Exercise support is given based on the Guidelines for National Fitness of China, Chinese and international guidelines of gestation diabetes. Phycological support is given by sending education articles on mental health. Participants are encouraged to update data about their diet, exercise and body weight through the APP, and based on the data investigators will individualize the suggestions.
Control group
Pregnant women randomized to the control group only have regular prenatal care in their local hospitals.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lifestyle intervention with APP
The face to face education class will be conducted by an obstetrician, an endocrinologist and a nutritionist together. Then the lifestyle intervention will be launched by an APP that installed in participants' private mobile phones, including nutrition, exercise and phycological support. Nutrition guidance is conducted according to the Chinese Dietary Guide, Chinese and international guidelines of gestation diabetes management. Exercise support is given based on the Guidelines for National Fitness of China, Chinese and international guidelines of gestation diabetes. Phycological support is given by sending education articles on mental health. Participants are encouraged to update data about their diet, exercise and body weight through the APP, and based on the data investigators will individualize the suggestions.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Fasting plasma glucose level ≥ 4.4 mmol/l.
2. Body mass index ≥ 24 kg/m\^2
3. Systolic blood pressure ≥ 130 mmHg, or diastolic blood pressure ≥ 80 mmHg.
4. First-degree family history of diabetes
5. History of GDM
6. History of polycystic ovary syndrome.
* Willing to keep reading the education articles and supporting materials that delivered by the mobile APP.
* Willing to provide informed consent.
Exclusion Criteria
* Fasting plasma glucose level value ≥5.6 mmol/l, or glycated hemoglobin value ≥ 5.6%.
* Continuous use of antidiabetic medicine for 7 days or more within the current 3 months
* Spontaneous abortion twice or more
* Body weight loss for 10% or more within the current 3 months
* History of other diseases including but not limited to:
1. Arteriosclerotic cardiovascular disease, heart failure or stroke
2. Systolic blood pressure ≥160 mmHg, or diastolic blood pressure ≥90 mmHg.
3. Hematological system diseases. For anemia patients, hemoglobin ≥90g/l is acceptable.
4. Renal dysfunction or liver dysfunction
5. Rheumatic diseases, currently receiving glucocorticoids or other immunosuppressors
6. Serious diseases of respiratory system with current use of glucocorticoids.
7. Diseases of endocrine system. But it is acceptable that the hypothyroidism has been controlled with levothyroxine.
* Other conditions that investigators consider inappropriate for this study.
30 Years
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking University Third Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hong Tianpei, MD,PhD
Role: PRINCIPAL_INVESTIGATOR
Department of Endocrinology and Metabolism, Peking University Third Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Haidian Maternal&Child Health Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DIGITAL-G-2019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.